ALIGOS THERAPEUTICS INC's ticker is ALGS and the CUSIP is 01626L105. A total of 57 filers reported holding ALIGOS THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $2,649,631 | -23.1% | 3,547,030 | 0.0% | 0.29% | +21.8% |
Q2 2023 | $3,444,166 | +11.1% | 3,547,030 | 0.0% | 0.24% | +10.7% |
Q1 2023 | $3,100,104 | +91619.1% | 3,547,030 | 0.0% | 0.22% | -44.7% |
Q4 2022 | $3,380 | -99.9% | 3,547,030 | 0.0% | 0.39% | -9.7% |
Q3 2022 | $3,902,000 | -9.1% | 3,547,030 | 0.0% | 0.43% | 0.0% |
Q2 2022 | $4,292,000 | -43.7% | 3,547,030 | 0.0% | 0.43% | -17.9% |
Q1 2022 | $7,626,000 | -81.9% | 3,547,030 | 0.0% | 0.52% | -79.3% |
Q4 2021 | $42,103,000 | -23.5% | 3,547,030 | 0.0% | 2.54% | +2.8% |
Q3 2021 | $55,014,000 | -23.9% | 3,547,030 | 0.0% | 2.47% | -21.1% |
Q2 2021 | $72,306,000 | -10.4% | 3,547,030 | 0.0% | 3.13% | +10.4% |
Q1 2021 | $80,659,000 | -17.8% | 3,547,030 | 0.0% | 2.84% | -35.2% |
Q4 2020 | $98,075,000 | – | 3,547,030 | – | 4.38% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Versant Venture Management, LLC | 2,320,381 | $47,301,000 | 15.67% |
Pivotal bioVenture Partners Investment Advisor LLC | 876,548 | $17,873,000 | 7.04% |
Vivo Capital, LLC | 3,547,030 | $72,306,000 | 3.13% |
Novo Holdings A/S | 2,614,563 | $53,311,000 | 2.36% |
ACUTA CAPITAL PARTNERS, LLC | 214,254 | $4,368,000 | 1.75% |
Boxer Capital, LLC | 1,526,048 | $31,108,000 | 1.10% |
VR Adviser, LLC | 408,377 | $8,325,000 | 1.01% |
Cormorant Asset Management, LP | 905,467 | $18,458,000 | 0.63% |
HHLR ADVISORS, LTD. | 2,165,064 | $44,135,000 | 0.45% |
Logos Global Management LP | 212,785 | $4,339,000 | 0.36% |